Lambrecht E R, van der Loos T L, van der Eerden A H
Department of Internal Medicine, De Wever Hospital, Heerlen, The Netherlands.
Int Ophthalmol. 1987 Oct;11(1):13-5. doi: 10.1007/BF02027892.
A 63-year-old man with a metastasising pancreatic glucagonoma is described, who presented with progressive deterioration of vision and bilateral central scotomata as the first symptom. This patient was treated with dacarbazine (DTIC) 250 mg/m2 IV daily for five consecutive days at 4-week intervals. The vision returned completely to normal, in a clinical and biochemical remission. Although there is no wide experience in treatment, the literature seems to indicate that DTIC should be the drug of choice in treating metastatic glucagonoma. Central scotomata may be a new 'paraneoplastic' symptom and a key to the earlier diagnosis of the glucagonoma syndrome by ophthalmologists, just as necrolytic migratory erythema has been for the dermatologists.
本文描述了一名63岁患有转移性胰高血糖素瘤的男性患者,其首发症状为视力进行性下降和双侧中央暗点。该患者接受了达卡巴嗪(DTIC)治疗,剂量为250mg/m²,静脉注射,每日一次,连续五天,每4周重复一次。视力完全恢复正常,临床和生化指标均缓解。尽管在治疗方面经验有限,但文献似乎表明DTIC应是治疗转移性胰高血糖素瘤的首选药物。中央暗点可能是一种新的“副肿瘤性”症状,是眼科医生早期诊断胰高血糖素瘤综合征的关键,就如同坏死性游走性红斑对皮肤科医生而言一样。